52 -11 (85) 2025 - Raupov A.O. - CLINICAL EFFICACY OF REBAMIPIDE AND PROTON PUMP INHIBITOR COMBINATION IN THE COMPLEX TREATMENT OF ACID-DEPENDENT GASTROINTESTINAL DISEASES IN PATIENTS WITH ISCHEMIC HEART DISEASE

CLINICAL EFFICACY OF REBAMIPIDE AND PROTON PUMP INHIBITOR COMBINATION IN THE COMPLEX TREATMENT OF ACID-DEPENDENT GASTROINTESTINAL DISEASES IN PATIENTS WITH ISCHEMIC HEART DISEASE

Raupov A.O. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

Acid-dependent gastrointestinal diseases accompanying ischemic heart disease represent one of the most challenging comorbid conditions in modern clinical practice. These disorders often develop against the background of antiplatelet therapy, reducing both treatment efficacy and patient quality of life. The aim of this study was to evaluate the clinical efficacy of combining proton pump inhibitors (PPIs) with rebamipide in the complex treatment of patients with ischemic heart disease and acid-dependent gastrointestinal diseases. A total of 120 patients were enrolled between 2023 and 2025. The results demonstrated that the addition of rebamipide to PPI therapy significantly accelerated mucosal regeneration, reduced erosive-ulcerative lesions, and decreased proinflammatory cytokine levels (IL-1β, IL-6, TNF-α). Moreover, prostaglandin E₂ (PGE₂) concentration increased toward physiological levels. Clinical and endoscopic findings confirmed the safety and high efficacy of the combination therapy. Therefore, rebamipide combined with PPIs can be recommended as an optimized, evidence-based, and clinically effective approach in the complex treatment of acid-dependent gastrointestinal diseases in patients with ischemic heart disease.

Keywords: Ischemic heart disease, acid-dependent gastrointestinal diseases, rebamipide, proton pump inhibitors, complex treatment, gastroprotective therapy, clinical efficacy.

First page

299

Last page

304

For citation:Raupov A.O. - CLINICAL EFFICACY OF REBAMIPIDE AND PROTON PUMP INHIBITOR COMBINATION IN THE COMPLEX TREATMENT OF ACID-DEPENDENT GASTROINTESTINAL DISEASES IN PATIENTS WITH ISCHEMIC HEART DISEASE//New Day in Medicine 11(85)2025 299-304 https://newdayworldmedicine.com/en/new_day_medicine/11-85-2025

List of References

1. Raupov A. O. (2025). Optimizing gastrointestinal protection in ischemic heart disease patients receiving dual antiplatelet therapy: Modern strategies for the prevention and management of acid-dependent diseases. // Ilmiy va innovatsion terapiya 2025;(4):12-29. https://ivit.uz//upload/1760810863post_file.pdf
2. Nurbaev F.E., Raupov A.O. (2025). Comorbidity of acid related gastrointestinal disorders and ischemic heart disease: Modern perspectives on shared risk factors and pathophysiological mechanisms (literature review). // New Day in Medicine, 2025;5(79)86-90. https://newdayworldmedicine.com/upload_files/journal_article/682783f42a901.pdf
3. Raupov A.O. (2025). Contemporary views on common risk factors and pathophysiological mechanisms of acid-related gastrointestinal disorders and ischemic heart disease. // Journal of Innovation in Educational and Social Research, 2025;3(10):14-17. ISSN 2992-894X. http://journals.proindex.uz
4. Raupov A.O. (2025). Contemporary approaches to treating and preventing acid-dependent digestive tract disorders in patients with ischemic heart disease. // Journal of Innovation in Educational and Social Research, 2025;3(10):18-22. http://journals.proindex.uz
5. Raupov A.O. (2025). In cases of ischemic heart disease, mucosal alterations in the upper gastrointestinal tract. // Journal of Innovation in Educational and Social Research, 2025;3(10):5-8. http://journals.proindex.uz
6. Raupov A.O. (2025). The problem of aspirin-induced gastrointestinal tract lesions in patients with stable ischemic heart disease receiving acetylsalicylic acid. // Journal of Innovation in Educational and Social Research, 2025;3(11):1-4. https://journals.proindex.uz
7. Raupov A.O. (2025). Mechanisms of the development of aspirin-induced gastroduodenopathies in patients with ischemic heart disease during acetylsalicylic acid therapy. // Journal of Innovation in Educational and Social Research, 2025;3(11):5-9. https://journals.proindex.uz
8. Raupov A.O. (2025). Pharmacological approaches to the management of aspirin-induced gastroduodenopathies in patients with ischemic heart disease – traditional strategies. // Journal of Innovation in Educational and Social Research, 2025;3(11):10-15. https://journals.proindex.uz
9. Raupov A.O. (2025). Prospects for the use of drugs affecting the protective mechanisms of the gastrointestinal mucosa: The role of prostaglandin production stimulators. // Journal of Innovation in Educational and Social Research, 2025;3(11):16-19. https://journals.proindex.uz
10. Raupov A.O. (2025). Thromboembolic complications in cardiovascular diseases: Pathophysiological mechanisms and modern approaches to prevention. // Journal of Innovation in Educational and Social Research, 2025;3(11):20-22. https://journals.proindex.uz
11. Raupov A.O. (2025). Evidence-based approaches to the prevention and treatment of NSAID-induced gastrointestinal injury. // American Journal of Bioscience and Clinical Integrity, 2025;2(11):38-44. https://biojournals.us/index.php/AJBCI
12. Raupov A.O. (2025). The role of acetylsalicylic acid in the prevention of cardiovascular complications in patients with stable ischemic heart disease. // American Journal of Bioscience and Clinical Integrity, 2025;2(11):66-70. https://biojournals.us/index.php/AJBCI

    file

    download